Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
18 Julho 2023 - 8:00AM
Business Wire
Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company
pioneering a new and differentiated class of therapeutics based on
its proprietary bicyclic peptide (Bicycle®) technology, today
announced the closing on Monday, July 17, 2023 of its underwritten
public offering of 6,117,648 American Depositary Shares (“ADSs”),
each representing one ordinary share, which includes 1,411,764 ADSs
sold upon the underwriters’ full exercise of their option to
purchase additional ADSs, and 4,705,882 non-voting ordinary shares.
The offering resulted in gross proceeds of approximately $230.0
million, before deducting underwriting discounts and commissions
and offering expenses payable by Bicycle.
Goldman Sachs & Co. LLC, Jefferies and Leerink Partners
acted as joint book-running managers for the offering. The ADSs
were offered pursuant to a “shelf” registration statement on Form
S-3ASR that was filed by Bicycle with the Securities and Exchange
Commission and automatically became effective upon filing. The
offering was made only by means of a prospectus supplement and
accompanying prospectus, copies of which may be obtained from:
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200
West Street, New York, New York 10282, telephone: 1-866-471-2526,
or by email at prospectus-ny@ny.email.gs.com; Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, New York, New York 10022, or by email at
Prospectus_Department@Jefferies.com; or Leerink Partners LLC,
Attention: Syndicate Department, 53 State Street, 40th Floor,
Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext.
6105, or by email at syndicate@leerink.com.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230718530286/en/
David Borah, CFA SVP, Capital Markets & Corporate
Communications david.borah@bicycletx.com 617-203-8300
Bicycle Therapeutics (NASDAQ:BCYC)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Bicycle Therapeutics (NASDAQ:BCYC)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024